Multi-Specialty Physician Panel Weighs in on Likely Positioning for Lilly/Daiichi's Prasugrel
SCOTTSDALE, Ariz., Feb. 20 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing anticoagulant therapies. This report is based on primary interviews conducted with cardiovascular experts from North America and Europe immediately following the American Society of Hematology (ASH) annual meeting.
"Anticoagulation therapy is being studied in a variety of settings, including elective and non-elective surgery, acute coronary syndrome, prevention and treatment of deep vein thrombosis/pulmonary embolism, secondary prevention of strokes in patients being treated for atrial fibrillation, and oncology," says Jeff Berk, MedPredict president. "Our Thought Leaders share their opinions on antithrombotics and antiplatelets driven by different patient populations and differing therapeutic goals."
The report addresses the following questions:
"Our panel reviews all of the key compounds in the pipeline and distills a massive amount of information down to the most critical insights drug developers should have for decision-making," according to Dr. Berk.
Companies mentioned in this report include: Astellas, AstraZeneca, Bayer-Schering, Bristol-Meyers Squibb, Daiichi Sankyo, GlaxoSmithKline, Lilly, Pfizer, Portola, Sanofi-Aventis, Schering-Plough, Takeda, The Medicines Company.
This report can be purchased by contacting MedPredict (www.medpredict.com).
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
Copyright©2009 PR Newswire.
All rights reserved